Wenying Peng, Liming Cao, Likun Chen, Gen Lin, Bo Zhu, Xiaohua Hu, Yingcheng Lin, Sheng Zhang, Meilin Jiang, Jingyi Wang, Junjun Li, Chao Li, Lin Shao, Haiwei Du, Ting Hou, Zhiqiu Chen, Jianxing Xiang, Xingxiang Pu, Jia Li, Fang Xu, Herbert Loong, Lin Wu
BACKGROUND: Pulmonary neuroendocrine tumors (pNETs) include typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell lung carcinoma (SCLC). The optimal treatment strategy for each subtype remains elusive, partly due to the lack of comprehensive understanding of their molecular features. We aimed to explore differential genomic signatures in pNET subtypes and identify potential prognostic and therapeutic biomarkers. METHODS: We investigated genomic profiles of 57 LCNECs, 49 SCLCs, 18 TCs, and 24 ACs by sequencing tumor tissues with a 520-gene panel and explored the associations between genomic features and prognosis...
March 4, 2022: Oncologist